29 JUL 2024

DOTBIO ANNOUNCES Collaboration with Protect Animal Health (PAH) to Develop Cutting-Edge Therapies and Technologies for animal health

This collaboration between PAH and DotBio will leverage PAH’s knowledge in veterinary medicine, and DotBio’s expertise and proprietary methodologies in antibody discovery and engineering, to identify and develop novel therapeutic antibodies for treating canine and feline patients.

24 jUL 2024

DotBio presents at BIO Asia-Taiwan

14 JUN 2024

DotBio develops teVLP for intracellular antibody specific delivery

We have filed for patents for the teVLP technology

21 MAY 2024

DotBio’s team expands

The newly minted NTU graduates, Chi Kiat Yeo and Lim Zhi Xian, join us as Research Associates. They will be working on production and optimization of antibodies for intracellular applications.

12 MAY 2024

DotBio attends BioEquity Europe 2024, San Sebastián, Spain

24 APR 2024

DotBio attends the AsiaBio conference, Singapore

4 mar 2024

DotBio attends the BioCentury Biopharma summit, Singapore

4 Mar 2024

DB007 enters animal efficacy studies

Our lead candidate, DB007, has begun animal efficacy studies. DB007 is a tri-specific antibody designed to reinvigorate exhausted immune cells to fight cancer more effectively. This study was conducted in the Agency for Science, Technology and Research (A*STAR).

23 FEB 2024

DotBio’s team expands

Dr Elena Okina joins us as project manager, spearheading our projects in Cancer Immunology

10 FEB 2024

DotBio attends BIO CEO and Investor Conference, New York

17 OCT 2023

DotBio attends the BIO Investor Forum, San Francisco

12 OCT 2023

DotBio attends as exhibitor at NTUitive Technology Roadshow 2023, Singapore

3 OCT 2023

DotBio’s team expands

Dr Erica Ceccarello joins us as scientist in our Cancer Immunology team.

20 SEP 2023

DotBio attends ChinaBIO Partnering Forum 2023, Shanghai

7 Sep 2023

DotBio announces that its partner Junshi Biosciences has received approval from NMPA to advance JS207 into clinical studies

JS207 is an exciting, highly targeted, next-generation cancer therapy that was rapidly designed using the DotBody platform technology. JS207 is a very specific combination of an anti-VEGF DotBody module and Junshi Biosciences’ anti-PD-1 antibody that addresses tumor growth and the tumor’s immune evasion tactics simultaneously.

11 Aug 2023

DotBioHK graduation from Incu-Bio program

DotBio was invited to present in the HKSTP (Hong Kong Science and Technology Parks Corporation) Incu-Bio Open Day as part of the graduating companies of the Incu-Bio program.

7 Aug 2023

DotBIO COMPLETES US$5.6 M PRE-SERIES a ROUND

DotBio has secured $5.6 million in its Pre-Series A funding round space led by specialist life sciences investors Proxima Ventures and Gaorong Capital, Chaperone Investment, Protect Biotech, and AIM-HI Accelerator Fund.

26 Jul 2023

BIO-Asia Taiwan

DotBio’s CEO, Dr. Ignacio Asial, attended the BIO Asia–Taiwan 2023 conference both as a panelist and a presenter.

19 Jun 2023

Junshi Biosciences reached IND Filing

Our most advanced partnered molecule (JS207 - a recombinant humanized anti-PD-1/VEGF bispecific) reached IND filing.

5 Jun 2023

BIO International Boston

DotBio’s CEO, Dr. Ignacio Asial, presented our technological advancement to several potential investors and pharmaceutical companies.

5 MAY 2023

Asia BIO, Virtual

DotBio attended this virtual conference and secured partnering meetings with several global pharmaceutical companies.

26 APR 2023

Asia BIO, Singapore

DotBio’s CEO, Dr. Ignacio Asial, presented our technological advancement to several potential investors and pharmaceutical companies.

14 MAR 2023

Digital RESI

Our Business Development and Operations Associate, Ke Xin Lui, attended the digital conference and secured several potential investment discussions.

27 Feb 2023

DotBio’s team expands

DotBio is pleased to welcome a new team member to our family! After a successful internship with DotBio in 2022, Mahirah Amin joins us just after graduation as a full-time Research Officer. She will be involved in carrying out cell-based assays for antibody characterization.

5 Feb 2023

DotBio’s CEO visits Hong Kong team and partners

Following the relaxation of travel restrictions in Hong Kong, Ignacio Asial visited DotBio’s Hong Kong team as well as partners at Uni-Bio and Alephoson. The trip included site visits for a planned lab expansion.

11 Nov 2022

DotBio attends ChinaBio partnering conference

DotBio attended this conference virtually and secured partnering meetings with several global pharmaceutical companies.

2 Nov 2022

DotBio attends BIO-Europe partnering conference

DotBio presented our technological advancement to several potential investors and pharmaceutical companies.

21 Sep 2022

DotBio attends RESI Boston investment conference

In this in-person event, DotBio presents its platform to several pharma companies and investors.

19 Sep 2022

DotBio’s roadshow in the United States

DotBio presents its technology platform to several pharmaceutical companies in Boston and San Francisco, from 19 September to 29 September 2022. Two of them proceed to specific collaboration discussions.

30 AUG 2022

DotBio announces publication in RSC Chemical Biology

This peer-reviewed scientific article validates the use of the DotBody technology to using the DotBody technology to convert disulfide- dependent cyclic peptides into disulfide-free intracellular antibodies. Disulfide-constrained peptide libraries, such as the New England Biolabs Ph.D.TM libraries are widely used by researchers to generate binding peptides. However, the use of these peptides to interrogate intracellular pathways is difficult since the disulfides tend to dissolve inside the cells, and the peptides lose structural integrity. In this work, we demonstrate the grafting of a disulfide-containing peptide into our disulfide-free human-derived and stabilized VH technology leads to a disulfide-free antibody able to bind and block its target inside mammalian cells.

23 AUG 2022

DotBio announces publication in Nature Communications.

This peer-reviewed scientific article validates the use of DotBio's autonomous and disulfide-free DotBody technology to modulate intracellular pathways and to interrogate the eIF4F complex through eIF4E blockade. eIF4E is overexpressed and/or misregulated in many tumors and linked to resistance to chemotherapy. The paper shows that its specific blockade with a picomolar affinity anti-eIF4E DotBody can target intracellular pathways specifically and inhibit growth of cancer cell lines.

27 JUL 2022

DotBio attends BIO Asia-Taiwan

DotBio attended this meeting virtually, and secured partnering meetings with several global pharmaceutical companies.

30 May 2022

DotBioHK successfully completes incubator milestone assessment

DotBio’s Hong Kong team presented the latest company progress to Hong Kong Science and Technology Park (HKSTP), as part of the IncuBio program, and successfully completed the milestone assessment.

28 MAR 2022

DotBio attends BIO Europe Spring conference

Our Business and Operations Associate, Ke Xin Lui, attended this partnering conference, and secured several new partnership leads.

22 MAR 2022

DotBio attends RESI conference

Our Business and Operations Associate, Ke Xin Lui, attended this fundraising conference, and secured several new leads.

1 Mar 2022

DotBio’s team expands

DotBio is pleased to welcome a new team member to our family! Vinoshini Selvathurai joins as a Research Associate in the antibody characterization and protein production team.

22 FEB 2022

DotBio and A*STAR submit 2nd joint scientific publication

DotBio announces a new scientific publication in collaboration with Dr. Christopher Brown and his team at A*STAR - Agency for Science, Technology and Research. The paper describes the use of DotBio's intracellular, disulphide-free DotBody technology to study the activity of a new peptide aptamer directed against eIF4E Capped-mRNA Binding Site, using a newly developed methodology: Peptide Epitope Linker Evolution (PELE). eIF4E is overexpressed and/or misregulated in many tumors and linked to resistance to chemotherapy, making it a potential intracellular target for cancer therapy. The paper can be read here.

25 JAN 2022

DotBio’s team expands

DotBio is pleased to welcome new additions to our family! Ke Xin Lui will be our Business and Operations Associate, managing business development and daily operations. Zi Qi Ong joins as a Research Associate in the antibody characterization and protein production team.

5 JAN
2022

Junshi Biosciences and DotBio Announce Collaboration to Develop next-generation antibody therapy with DotBody Module

Junshi Biosciences will obtain the license to one of DotBio’s DotBody modules, to be used within the oncology field for the development of several multi-specific antibodies. DotBio will be entitled to upfront and milestone payments, as well as royalties as the molecules progress through clinical development, regulatory approvals, and commercialization.

1 DEC 2021

DotBio-CStone’s first project starts

CStone’s and DotBio’s scientific teams met virtually to kickstart their first project, under their multi-molecule partnership.

9 nov 2021

CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics

The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the molecules. CStone will also take an equity position in DotBio, and provide incubation space at CStone Global R&D Headquarters and Industrialization Base in Suzhou.

20 Aug 2021

DotBio a finalist in Jinji Lake Startup competition

DotBio’s COO, Kelly Hew, delivered a powerful 6- minute pitch that propelled DotBio into the competition’s industry finals. The event generated more exposure for the company and its plans to expand into the China market.

18 Aug 2021

JP patent application granted

Japanese patent application was granted by the Japan Patent Office. The patent, held by Nanyang Technological University and licensed to DotBio exclusively, provides protection on the core DotBody technology.

17 Aug 2021

DotBio first to join HKSTP AstraZeneca co-incubator program

DotBio became the first company accepted into the Hong Kong Science and Technology Park (HKSTP) – AstraZeneca co-incubation program. Under the program, AstraZeneca will support and connect start-ups with key stakeholders and partners who can provide a clearer understanding of industry and related opportunities. Additionally, AstraZeneca will leverage its existing networks with Mainland China and global markets to provide platforms for exploring opportunities overseas.

6 JUL 2021

US PATENT APPLICATION GRANTED

DotBio’s US patent application for the core DotBody technology is officially approved by the US Patent and Trademark Office. This patent provides protection to the core DotBody technology. The DotBody template allows DotBio to generate new domain antibodies synthetically against any given therapeutic target rapidly and efficiently. 

21 JUN 2021

NOTICE OF ALLOWANCE, JAPAN PATENT

DotBio’s Japanese patent application for the core DotBody technology received the Notice of Allowance by the Japan Patent Office.

1 JUN 2021

NOTICE OF ALLOWANCE, US PATENT

DotBio’s US patent application for the core DotBody technology received the Notice of Allowance by the US Patent and Trademark Office.

12 MAY 2021

DOTBIO PARTICIPATES IN CHINABIO CONFERENCE

DotBio participated in the ChinaBio’s hybrid conference which was held in Shanghai. The conference linked DotBio to several potential partners and strengthened DotBio’s foothold in China.

10 MAR 2021

DotBio announces partnership with Uni-Bio SCIENCE GROUP

The partnership brings together DotBio's superior stabilized and humanized VH domain (DotBody) technology platform, and Uni-Bio's strong expertise in prokaryotic scale-up systems and clinical development. We look forward to developing together the next generation of therapies to solve unmet clinical needs in the ophthalmology space.

9 MAR 2021

DotBio joins the AIM-HI Accelerator Fund's Accelerator Program

This is an important partnership that allows DotBio to tap into AIM-HI's business expertise and excellent network of industry leaders. This will strengthen DotBio's work in the translation of new antibody technologies towards cancer drug development, and accelerate our efforts to bring new superior therapies to patients.

28 JAN 2021

DotBio signs term sheet with third pharmaceutical company

The deal involves the out-licensing of certain DotBio assets, and includes upfront, milestone and royalty payments. Details to be announced.

12 JAN 2021

DotBio attends virtual JPM Conference

With COVID-19 restrictions in place, DotBio joins other industry players at the BIO One-on-one Partnering event at JPM conference, held virtually this year. In this global partnering event, which gathers all major players in the Healthcare industry, DotBio established contact with new potential pharmaceutical partners, and continued conversations with existing ones.

4 JAN 2021

Tumor-on-a-chip project starts

DotBio has partnered Dr. Andrea Pavesi (from Singapore’s Institute of Cellular and Molecular Biology) and AIM Biotech to integrate tumor-on-a-chip technology into its antibody discovery platform. These partners have a solid track record, with publications in top-tier scientific journals validating the technology.

1 JAN 2021

Dr. Ignacio Asial becomes Adjunct Assistant Professor at NTU

DotBio’s CEO, Dr. Ignacio Asial, joins his alma mater Nanyang Technological University, as Adj. Asst. Prof. His first course is titled “Discovery and Development of Therapeutic Antibodies”.

16 NOV 2020

S$250,000 grant secured

DotBio obtained a S$250,000 Proof-of-Concept grant from Enterprise Singapore. This will be used to incorporate tumor-on-a-chip technology into DotBio’s antibody discovery platform.

23 OCT 2020

DotBio signs term sheet with second pharmaceutical company

The deal involves the co-development of several DotBody-based therapies for non-oncology applications. Details to be announced.

12 OCT 2020

DotBio signs term sheet with pharmaceutical company

The deal involves the IND-development of DotBio’s lead programme. Details to be announced.

1 OCT 2020

DotBio secures investment from Nanyang Technological University

Nanyang Technological University’s innovation and enterprise company, NTUitive Pte. Ltd., invests S$500,000 in DotBio through their Strategic Research Investment Fund.

15 SEP 2020

DotBio attends RESI Digital investment conference

This conference allowed DotBio to connect with investors and potential partners worldwide.

25 AUG 2020

DotBio attends ChinaBio virtual partnering conference

EBD Group’s ChinaBio conference goes virtual. DotBio attended remotely, with the focus on establishing new partnerships and contacts.

29 JUN 2020

DotBio presents at Guangzhou International Bio Island’s Roadshow

DotBio’s COO, Dr. Kelly Hew, introduced the company to the Guangdong investment community.

20 JUN 2020

DotBio attends SAPA conference

DotBio participated at the Sino-American Pharmaceutical Professionals Association’s digital conference, with the support from Hong Kong Science and Technology Park. The meeting led to several new contacts within the global pharmaceutical investment community.

18 JUN 2020

DotBio presents at MyBioGate China Focus

This roadshow, organized by MyBioGate, allowed DotBio to introduce the company to investors and potential partners in China.

8 JUN 2020

DotBio attends RESI Digital

The Redefining Early Stage Investments (RESI) conference is an international conference focusing on early-stage start-up investments. It allowed DotBio to connect with new investors

8 JUN 2020

DotBio attends BIO International

This conference, held for the first time virtually, allowed DotBio to connect with investors and potential partners worldwide.

8 Apr 2020

DotBioHK expands therapeutic focus

DotBio’s subsidiary in Hong Kong was set up to expand DotBio’s capabilities into new therapeutic areas. As the operations become more established, DotBioHK is expanding its focus to metabolic disorders, ophthalmology and inflammatory conditions.

23 Feb 2020

AFCR invests in DotBio

The Asian Fund for Cancer Research is a non-profit organization committed to funding cancer research, especially those cancers prevalent in Asian populations. It also promotes high-impact global collaborations to save the lives of cancer patients. AFCR’s investment will help accelerate DotBio’s growth by leveraging its network of donors, investors, oncologists and healthcare institutions.

12 JAN 2020

DotBio attends China Showcase and Biotech Showcase (San Francisco, USA)

These annual conferences, held in parallel to JP Morgan Healthcare summit, attract global investors and pharmaceutical companies.

15 Nov 2019

Dr. Harry Lam joins as Advisor

Dr Harry Lam has an extensive career of over 30 years in the pharmaceutical industry. He has held senior management roles in biopharmaceutical manufacturing at pharmaceutical companies Genentech, Shire and Sanofi, as well as biotech startups KaloBios, Affinita, 23andMe and JW Therapeutics. He holds a B.Sc. in Chemical Engineering from University of Birmingham (UK) and a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute (USA).

11 Nov 2019

Dr. Zung Thai joins as Advisor

Dr. Zung Thai is a Physician Scientist with over 15 years of drug development experience. He has been involved in the design, execution, and interpretation of early and late clinical studies of novel small molecule, large molecule, cellular, and vaccine therapeutics in oncology, fibrosis, metabolic, and neurologic diseases. He has held senior management clinical development positions at pharmaceutical companies Amgen and Gilead, as well as startup companies Anza Therapeutics, Arresto Biosciences and Atara Biotherapeutics. Zung holds a B.A. from Cornell University (USA) and both a Ph.D. and M.D. from University of Pittsburgh School of Medicine (USA).

3 NOV 2019

Dr. Scott Ogg joins as Advisor

Dr. Scott Ogg brings extensive experience in venture strategy, corporate development and portfolio management. He has served as senior management for global pharmaceutical company Gilead, as well as biotech startup companies Nektar, Arresto Biosciences and ARMO Biosciences. Scott holds a B.Sc. in Biology from Albion College (USA), a Ph.D. in Cellular and Molecular Physiology from Tufts University (USA), a did his postdoctoral fellowship at Harvard Medical School (USA).

22 OCT 2019

DotBio presents at the BIO Investor Forum, San Francisco (USA)

This international investor meeting, held in San Francisco, attracts major global healthcare investors. DotBio presented the company and future development plans. Additionally, DotBio secured several meetings with investors and pharma companies to explore potential collaboration opportunities.

3 SEP 2019

DotBio presents at the 3rd Antibody-based Therapeutics Conference, Shanghai (China)

DotBio introduced the company, its unique antibody technologies and development plans at the 3rd Antibody-based Therapeutics Conference in Shanghai. During the trip, DotBio continued discussions with investors, and started discussions with CDMOs in preparation for IND-enabling studies.

FEB 2019

Prof. Pär Nordlund is appointed to the Nobel Prize Committee

DotBio's Scientific Founder joins the renowned group of scientists that selects the Nobel Prize of Medicine or Physiology.

6 JAN 2019

DotBio attends China Focus and Biotech Showcase at JPM2019, San Francisco

5 JAN 2019

DotBio launches its Hong Kong subsidiary, DotBioHK Limited

DotBio launched DotBioHK at Hong Kong’s Science and Technology Park. The subsidiary, which currently has 3 employees, will focus on partnerships and new opportunities in the China market.

10 DEC 2018

DotBio presents at the 4th Annual Peptides and Proteins Symposium, Singapore

1 NOV 2018

DotBio attends the Biotech Investment Summit, Singapore

17 OCT 2018

DOTBIO PRESENTS AT THE BIO INVESTOR FORUM

DotBio presents the company and latest updates at the 2018 BIO Investor Forum, happening on October 17-18, 2018 in San Francisco.

5 SEP 2018

DotBio announces new advisors

Dr. Bertil Lindmark and Dr. Dineli Wickramasinghe join DotBio as scientific advisors.

6 AUG 2018

DOTBIO COMPLETES US$2.3M SEED ROUND

DotBio successfully launches to focus on next generation of immuno-oncology drugs based on domain antibodies.

NATURE COMMUNICATIONS 2013

Asial I, Cheng YX, Engman H, Dollhopf M, Wu B, Nordlund P, Cornvik T.

Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nature Communications. 2013; 4: 2901.